Proposed LCDs

When there are Proposed Local Coverage Determinations (LCDs) that are in the comment period, this webpage will provide a summary of comments received and Noridian's response. This information will remain on this webpage for at least six months.

Status Indicators

D = Proposed under development, not yet released for comment
C = Proposed LCD released for comment
E = Formal comment period has ended; comments now being considered
F = Final new/revised LCD has been issued for notice
A = Active policy: notice period complete and the policy is in effect

Send Proposed LCD Comments to:

Mail:
Noridian Medicare JE Part B
Attention: Proposed LCD Comments
PO Box 6781
Fargo, ND 58108-6781
Email: policydraft@noridian.com

X
 
Proposed LCD and LCA Title Release Date of Proposed LCD for Comment End Date for Comment Period Current Status Comments / Responses Date of Release for Notice Link to Final LCD
Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
08/04/22 09/17/22 E      
Epidural Steroid Injections for Pain Management

Billing and Coding: Epidural Steroid Injections for Pain Management
02/10/22 03/26/22 F View 05/05/22 View
MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer

Billing and Coding: MolDx: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
05/20/21 07/03/21 F View 06/23/22 View
MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
05/20/21 07/31/21 F View 06/23/22 View
MolDX: Melanoma Risk Stratification Molecular Testing

Billing and Coding: MolDx: Melanoma Risk Stratification Molecular Testing
05/20/21 07/03/21 F View 06/23/22 View
MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

Billing and Coding: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
07/07/22 08/20/22 E      
MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis 10/06/22 11/19/22 C      
MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia

Billing and Coding: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia
04/28/22 06/11/22 E      
MolDX: Plasma-Based Genomic Profiling in Solid Tumors

Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors
01/20/22 03/05/22 F      
MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer

Billing and Coding: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer
07/14/22 08/27/22 E      
Nerve Blockade for Treatment of Chronic Pain and Neuropathy

Billing and Coding: Nerve Blockade for Treatment of Chronic Pain and Neuropathy
04/28/22 06/11/22 F View 07/21/22

View

Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease

Billing and Coding: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease
01/20/22 03/05/22 F View 08/04/22 View
Sacroiliac Joint Injections and Procedures

Billing and Coding: Sacroiliac Joint Injections and Procedures
09/29/22 11/12/22 C      

 

When a "Draft" LCD becomes "Final/Future," go to the Future LCD page to view a specific future LCD.

  • View All Future LCDs by state. Within the table, each state selection will redirect you to the MCD on the CMS website. Note: All LCDs for JE states are the same.

 

Last Updated Fri, 07 Oct 2022 12:26:14 +0000